The present clinical trial was undertaken to investigate the @entity137 and antimyeloma activity of @entity1863 (BU) and @entity786 (CY) at the maximum tolerated doses of, respectively, 16 mg/kg and 200 mg/kg (BU-CY 4) as conditioning therapy for allogeneic bone marrow transplantation (BMT) in 19 consecutive @entity1 with @entity1582 ( @entity1582 ). Twelve (63%) had failed to respond to prior chemotherapy, while the remaining 37% had chemosensitive disease. No life-threatening or fatal regimen-related complications were observed. The incidence of @entity5501 was zero according to Jones' criteria and 21% according to McDonald's system. Transplant-related mortality was 37%. Using stringent criteria, the frequency of complete remission (CR) was 42% among all @entity1 and 53% among those who could be evaluated. With a median follow-up of 21 months for all @entity1 and 66 months for survivors, the actuarial probability of survival and event-free survival at 4 years from BMT was 26% (95% CI: 7-46) and 21% (95% CI: 3-39), respectively. A more favorable outcome of transplantation was observed in the subgroup of @entity1 with chemosensitive disease who had a transplant-related mortality of 14%, an overall CR rate of 86% (95% CI: 49-97) and a 4-year projected probability of event-free survival of 57% (95% CI: 20-93). Four of these @entity1 are currently alive in continuous CR after 54, 66, 80 and 94 months, respectively. It is concluded that BU-CY 4 as conditioning for allogeneic transplantation for @entity1582 is associated with acceptable morbidity and relatively low mortality. This regimen exerts substantial antimyeloma activity, resulting in a high CR rate and durable responses, especially in @entity1 with chemosensitive disease. Long-lasting remission and probable cure is possible following allogeneic stem cell transplantation for @entity1582 .

High-dose XXXX and @entity786 are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive @entity1582 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['multiple myeloma', 'MM'] @entity5501 :: ('MESH:D006504', 'Disease') :: ['veno-occlusive disease of the liver'] @entity1863 :: ('MESH:D002066', 'Chemical') :: ['busulfan']
@entity1863 :: (MESH:D002066,Chemical) :: ['busulfan']
